Cronos Group/$CRON

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Cronos Group

Cronos Group Inc headquartered in Toronto, Canada, cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis primarily to Israel. In the U.S., the company has an option to acquire 5.9% of U.S. multistate operator PharmaCann on a fully diluted basis upon easing of federal prohibition.

Ticker

$CRON
Primary listing

Industry

Pharmaceuticals

Headquarters

Stayner, Canada

Employees

459

ISIN

CA22717L1013

Cronos Group Metrics

BasicAdvanced
$803M
17.74
$0.12
1.53
-

What the Analysts think about Cronos Group

Analyst ratings (Buy, Hold, Sell) for Cronos Group stock.

Bulls say / Bears say

Jefferies raised Cronos Group's stock target to C$3.23, citing potential positive scenarios such as entering the U.S. market, a merger with a more optimistic company, or additional investment from Altria Group. (Investing.com)
Cronos Group's 'Spinach' brand became the No. 1 recreational cannabis brand in Canada, and its 'Peace Naturals' brand leads the medical marijuana market in Israel, indicating strong market positions. (Nasdaq)
The Department of Health and Human Services proposed reclassifying marijuana to a lower-risk drug category, potentially benefiting companies like Cronos Group. (Markets Insider)
Jefferies maintained a Hold rating on Cronos Group, noting that current operations are not generating significant value and future prospects appear challenging. (Investing.com)
Cronos Group posted a net loss of $8.7 million in its latest quarter, indicating ongoing profitability challenges. (The Motley Fool)
The U.S. Drug Enforcement Administration delayed a public meeting about rescheduling cannabis until after the presidential election, raising concerns about potential delays in U.S. market entry for companies like Cronos Group. (The Motley Fool)
Data summarised monthly by Lightyear AI. Last updated on 7 Jul 2025.

Cronos Group Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Cronos Group Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $CRON

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs